Oxytocin Acetate

Few neuropeptides have been known for as long as oxytocin: its structure was worked out in the 1950s, and Vincent du Vigneaud received the Nobel Prize for it in 1955. It is a chain of nine amino acids, made in the hypothalamus and released into the blood through the posterior pituitary. It is a close relative of vasopressin; only two amino acids separate the two.

Research treats two fields of action separately:

• Peripheral: contraction of the uterus and milk let-down, the classical functions.
• Central: social behaviour, bonding, trust and the processing of stress. This field has turned oxytocin into a heavily studied modulator of social cognition over recent decades.

In studies with intranasal dosing, endpoints shifted in trust games, in social recognition and in empathy tasks. One point matters for context: a critical review from 2015 concluded that the well-known trust effect did not replicate well in follow-up studies, and that neither plasma measurements nor genetic associations deliver robust evidence.

The target is OXTR, the oxytocin receptor, a G-protein-coupled receptor found among other places in the amygdala, the hypothalamus and the prefrontal cortex. The half-life in blood is very short at three to five minutes. For the intranasal route there is evidence that the peptide reaches the central nervous system directly through the olfactory lining; experimental setups therefore use the nose for central questions and subcutaneous dosing for peripheral ones.

We list oxytocin strictly as a research compound. What you read here is a summary of the evidence.

Oxytocin is regarded as mild in studies, particularly when given intranasally. A few points are still worth knowing:

• Nasal lining: mild irritation or headache occurs occasionally with intranasal dosing.
• Smooth muscle: the OXTR also sits outside the brain. At higher doses the literature describes circulatory changes.
• Inconsistent behavioural effects: depending on context, studies found altered emotional processing and sometimes opposite social effects.
• Missing long-term data: there are no robust human studies on repeated dosing over longer periods. The short half-life only speaks to acute exposure.

This summary is no substitute for medical advice.

• Oxytocin increases trust in humans - the much-cited trust game study by Kosfeld and colleagues from 2005.
• Does Oxytocin Increase Trust in Humans? A Critical Review of Research - critical stocktaking from 2015: the trust effect could not be replicated reliably.
• Oxytocin, vasopressin, and human social behavior - review of behavioural, hormonal, genetic and brain findings on both peptides in humans.
• The neurobiology of attachment - places the neural basis of attachment in context from the molecular to the systems level.